CTLA4 and melanoma: Recent therapies that reverse this evasion, specifically via the inhibition of PD-1 and CTLA-4, termed “immune checkpoint blockade,” have shown durable responses for a portion of patients with solid tumors and are especially effective in melanoma and non–small cell lung cancer.